C12N 2750/14371
Demonstrated in vivo effect
C12N2750/14371 (Demonstrated in vivo effect) appears on 9 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 15
- Assignees
- 9
- Inventors
- 32
- Latest grant
- 22 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 1 |
| 2020 | 3 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Nucleic acid molecules and uses thereof for non-viral gene therapy22 Jul 2025US 12,364,774 B2Bioverativ Therapeutics Inc.
- Vaccine against porcine parvovirus13 Oct 2020US 10,799,578 B2
- Viral vectors for the treatment of retinal dystrophy4 Feb 2020US 10,550,404 B2Novartis AG
- Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof21 Jan 2020US 10,537,632 B2Boehringer Ingelheim Animal Health USA Inc.
- Vaccine against porcine parvovirus26 Nov 2019US 10,485,866 B2
- Nucleic acid molecules and uses thereof for non-viral gene therapy28 Aug 2025US 2025/0269067 A1Bioverativ Therapeutics Inc.
- Viral vectors for the treatment of retinal dystrophy12 Oct 2023US 2023/0323398 A1Novartis AG
- Closed-end dna production with inverted terminal repeat sequences23 Mar 2023US 2023/0091932 A1Bioverativ Therapeutics Inc.
- Engineered itr sequences and methods of use4 Aug 2022US 2022/0243201 A1Bioverativ Therapeutics Inc.
- Viral vectors for the treatment of retinal dystrophy18 Feb 2021US 2021/0047656 A1Novartis AG
Most cited
By later US patents
- Viral vectors for the treatment of retinal dystrophy13US 9,163,259 B2Novartis AG · 2015
- Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof2US 10,080,798 B2Merial Limited · 2018
- Method for brain cancer therapy by co-administration of a parvovirus and interferon-gamma2US 9,446,099 B2Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts · 2016
- Vaccine against porcine parvovirus1US 10,485,866 B22019
- Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof1US 10,537,632 B2Boehringer Ingelheim Animal Health USA Inc. · 2020